利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

42 条记录 (耗时 0.051 秒)

    Monoclonal antibodies against CD30 lacking in fucosyl residues
    24.
    发明授权
    Monoclonal antibodies against CD30 lacking in fucosyl residues 有权
    针对CD30的单克隆抗体缺乏岩藻糖基残基

    公开(公告)号：US08491898B2

    公开(公告)日：2013-07-23

    申请号：US13462566

    申请日：2012-05-02

    申请人： Josephine M. Cardarelli ,  Amelia Nancy Black

    发明人： Josephine M. Cardarelli ,  Amelia Nancy Black

    IPC分类号： A61K39/395 ,  A61K39/44

    CPC分类号： C07K16/2878 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/732

    摘要： The invention pertains to anti-CD30 antibodies that lack fucosyl residues. The antibodies of the invention exhibit increased antibody-dependent cellular cytotoxicity (ADCC) activity, including the ability to lyse CD30-expressing cell lines that are not lysed by the fucosylated form of the antibodies. The invention also provides host cells that express the anti-CD30 antibodies that lack fucosyl residues, wherein the host cells are deficient for a fucosyl transferase. Methods of using the antibodies to inhibit the growth of CD30+ cells, such as tumor cells, are also provided.

    摘要翻译： 本发明涉及缺乏岩藻糖基残基的抗-CD30抗体。 本发明的抗体表现出增加的抗体依赖性细胞毒性（ADCC）活性，包括裂解不被所述抗体的岩藻糖基化形式裂解的CD30表达细胞系的能力。 本发明还提供表达缺乏岩藻糖基残基的抗-CD30抗体的宿主细胞，其中宿主细胞对于岩藻糖基转移酶是缺陷的。 还提供了使用抗体抑制CD30 +细胞如肿瘤细胞生长的方法。

    IRTA-5 ANTIBODIES AND THEIR USES
    28.
    发明申请
    IRTA-5 ANTIBODIES AND THEIR USES 审中-公开
    IRTA-5抗体及其用途

    公开(公告)号：US20080187547A1

    公开(公告)日：2008-08-07

    申请号：US11958683

    申请日：2007-12-18

    申请人： Robert Graziano ,  Josephine M. Cardarelli ,  Thomas D. Kempe ,  Beth Cutter ,  Mohan Srinivasan

    发明人： Robert Graziano ,  Josephine M. Cardarelli ,  Thomas D. Kempe ,  Beth Cutter ,  Mohan Srinivasan

    IPC分类号： A61K39/395 ,  C07K16/18 ,  A61P43/00

    CPC分类号： C07K16/3061 ,  A61K2039/505 ,  C07K16/283 ,  C07K2317/21 ,  C07K2317/565 ,  C07K2317/92

    摘要： The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to IRTA-5 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting IRTA-5, as well as methods for treating various B cell malignancies, including non-Hodgkin's lymphoma.

    摘要翻译： 本发明提供以高亲和力特异性结合IRTA-5的分离的单克隆抗体，特别是人单克隆抗体。 还提供了编码本发明抗体的核酸分子，表达载体，宿主细胞和用于表达本发明的抗体的方法。 还提供了免疫偶联物，双特异性分子和包含本发明抗体的药物组合物。 本发明还提供了用于检测IRTA-5的方法，以及用于治疗各种B细胞恶性肿瘤（包括非霍奇金淋巴瘤）的方法。

    Human monoclonal antibodies that bind CXCR4
    29.
    发明授权
    Human monoclonal antibodies that bind CXCR4 有权
    结合CXCR4的人单克隆抗体

    公开(公告)号：US08450464B2

    公开(公告)日：2013-05-28

    申请号：US12444130

    申请日：2007-10-01

    申请人： Michelle Kuhne ,  Peter Brams ,  Dawn M. Tanamachi ,  Alan J. Korman ,  Josephine M. Cardarelli

    发明人： Michelle Kuhne ,  Peter Brams ,  Dawn M. Tanamachi ,  Alan J. Korman ,  Josephine M. Cardarelli

    IPC分类号： C07K16/28 ,  C07K16/00 ,  A61K39/395

    CPC分类号： C07K16/2866 ,  A61K47/6803 ,  A61K47/6849 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/73 ,  C07K2317/76

    摘要： The present disclosure provides isolated monoclonal antibodies that specifically bind to CXCR4 with high affinity, particularly human monoclonal antibodies. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting CXCR4, as well as methods for treating various cancers, inflammatory disorders and HIV infection using an anti-CXCR4 antibody of this disclosure.

    摘要翻译： 本公开提供以高亲和力特别是人单克隆抗体特异性结合CXCR4的分离的单克隆抗体。 还提供了编码本公开的抗体的核酸分子，表达载体，宿主细胞和用于表达本公开的抗体的方法。 还提供了免疫偶联物，双特异性分子和包含本公开的抗体的药物组合物。 本公开还提供了用于检测CXCR4的方法，以及使用本公开的抗CXCR4抗体治疗各种癌症，炎性疾病和HIV感染的方法。